FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W113163896> ?p ?o ?g. }

• W113163896 abstract "Background G-CSF is a novel therapy for ischemic heart disease (IHD), but its safety and efficacy in acute or ‘no option’ refractory IHD (R-IHD) remains unclear. Also, the few completed studies generally did not adapt G-CSF to IHD patients but merely administered G-CSF according to usual hematological practice. To address these issues we evaluated the safety and efficacy of G-CSF therapy in 20 patients (18 males, 2 females, mean age 62.4) with R-IHD. Three approaches were incorporated to enhance the efficacy of G-CSF in R-IHD: Repeated, controlled myocardial ischemia was induced during G-CSF therapy to activate myocardial chemokine expression as a homing signal for mobilized angioblasts; Two cycles of G-CSF were administered to enhance the likelihood of clinically meaningful angiogenesis; During the second cycle of G-CSF an intracoronary infusion of CD133+ cells was performed. Methods After baseline cardiac assessment (CA) (angina questionnaire, exercise stress test (EST), nuclear Sestamibi (MIBI) and dobutamine stress echocardiographic (DSE) imaging), patients received open-label G-CSF commencing at 10μg/kg s/c for 5 days, with an EST on days 4 and 6 (to facilitate angioblast trafficking). After 3 months CA and the same regimen of G-CSF +ESTs were repeated but in addition, leukapheresis and a randomized double blinded intracoronary infusion of CD133+ or unselected cells were performed. Final CA was 3 months thereafter. Results Eight events fulfilled pre-specified adverse event (AE) criteria, but despite the poor outlook and co-morbidities of R-IHD patients there were no deaths or AEs resulting in long-term sequelae. Administration of 2 cycles of G-CSF resulted in step-wise improvements in angina frequency, quality of life, EST performance and Duke treadmill score (all p < 0.005). Pre-specified MIBI and DSE results trended towards improvement (p > 0.1), while a composite post hoc computation indicated improved ischemia/perfusion compared to baseline (p = 0.025). Intracoronary infusion of CD133+ or unselected cells was safe but neither enhanced the response to G-CSF. Conclusions Administering G-CSF to R-IHD patients may be performed safely and shows promise as a therapy for debilitating angina. A phase II/III study of this therapy is warranted." @default.
• W113163896 created "2016-06-24" @default.
• W113163896 creator A5002129758 @default.
• W113163896 creator A5008779269 @default.
• W113163896 creator A5010948114 @default.
• W113163896 creator A5021863838 @default.
• W113163896 creator A5024433568 @default.
• W113163896 creator A5025247920 @default.
• W113163896 creator A5031468937 @default.
• W113163896 creator A5050970018 @default.
• W113163896 creator A5055941340 @default.
• W113163896 creator A5068126583 @default.
• W113163896 creator A5074254969 @default.
• W113163896 creator A5077516392 @default.
• W113163896 date "2007-10-16" @default.
• W113163896 modified "2023-10-16" @default.
• W113163896 title "Abstract 2669: The Use of Granulocyte-Colony Stimulating Factor in Angina Patients to Stimulate Neovascularization: the GAIN I study" @default.
• W113163896 doi "https://doi.org/10.1161/circ.116.suppl_16.ii_591-d" @default.
• W113163896 hasPublicationYear "2007" @default.
• W113163896 type Work @default.
• W113163896 sameAs 113163896 @default.
• W113163896 citedByCount "0" @default.
• W113163896 crossrefType "journal-article" @default.
• W113163896 hasAuthorship W113163896A5002129758 @default.
• W113163896 hasAuthorship W113163896A5008779269 @default.
• W113163896 hasAuthorship W113163896A5010948114 @default.
• W113163896 hasAuthorship W113163896A5021863838 @default.
• W113163896 hasAuthorship W113163896A5024433568 @default.
• W113163896 hasAuthorship W113163896A5025247920 @default.
• W113163896 hasAuthorship W113163896A5031468937 @default.
• W113163896 hasAuthorship W113163896A5050970018 @default.
• W113163896 hasAuthorship W113163896A5055941340 @default.
• W113163896 hasAuthorship W113163896A5068126583 @default.
• W113163896 hasAuthorship W113163896A5074254969 @default.
• W113163896 hasAuthorship W113163896A5077516392 @default.
• W113163896 hasConcept C126322002 @default.
• W113163896 hasConcept C141071460 @default.
• W113163896 hasConcept C164705383 @default.
• W113163896 hasConcept C197934379 @default.
• W113163896 hasConcept C2776694085 @default.
• W113163896 hasConcept C2777767877 @default.
• W113163896 hasConcept C2778425758 @default.
• W113163896 hasConcept C500558357 @default.
• W113163896 hasConcept C71924100 @default.
• W113163896 hasConceptScore W113163896C126322002 @default.
• W113163896 hasConceptScore W113163896C141071460 @default.
• W113163896 hasConceptScore W113163896C164705383 @default.
• W113163896 hasConceptScore W113163896C197934379 @default.
• W113163896 hasConceptScore W113163896C2776694085 @default.
• W113163896 hasConceptScore W113163896C2777767877 @default.
• W113163896 hasConceptScore W113163896C2778425758 @default.
• W113163896 hasConceptScore W113163896C500558357 @default.
• W113163896 hasConceptScore W113163896C71924100 @default.
• W113163896 hasIssue "suppl_16" @default.
• W113163896 hasLocation W1131638961 @default.
• W113163896 hasOpenAccess W113163896 @default.
• W113163896 hasPrimaryLocation W1131638961 @default.
• W113163896 hasRelatedWork W2035030275 @default.
• W113163896 hasRelatedWork W2049397185 @default.
• W113163896 hasRelatedWork W2083251056 @default.
• W113163896 hasRelatedWork W2090650893 @default.
• W113163896 hasRelatedWork W2135975603 @default.
• W113163896 hasRelatedWork W2169404695 @default.
• W113163896 hasRelatedWork W2237746437 @default.
• W113163896 hasRelatedWork W2399063111 @default.
• W113163896 hasRelatedWork W2415765772 @default.
• W113163896 hasRelatedWork W2431594074 @default.
• W113163896 hasVolume "116" @default.
• W113163896 isParatext "false" @default.
• W113163896 isRetracted "false" @default.
• W113163896 magId "113163896" @default.
• W113163896 workType "article" @default.